NASDAQ: PTPIPetros Pharmaceuticals Inc Stock
$0.34-0.02 (-5.56%)
Updated Oct 7, 2024
PTPI Price
$0.34
Fair Value Price
N/A
Market Cap
$3.27M
52 Week Low
$0.28
52 Week High
$2.27
P/E
-0.05x
P/B
0.4x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.12M
Earnings
-$7.06M
Gross Margin
70.2%
Operating Margin
-159.3%
Profit Margin
-501%
Debt to Equity
1.98
Operating Cash Flow
-$9M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTPI Overview
Petros Pharmaceuticals, Inc. develops and commercializes therapeutics for men's health issues (erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders). lt markets its own line of ED products in the form of vacuum erection devices through its subsidiary, Timm Medical, Inc. Petros Pharmaceuticals was founded in 2020 and is headquartered in New York, NY.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PTPI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTPI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTPI is good value based on its book value relative to its share price (0.4x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.26x)
P/B vs Industry Valuation
PTPI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PTPI due diligence checks available for Premium users.
Be the first to know about important PTPI news, forecast changes, insider trades & much more!
PTPI News
Valuation
PTPI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
19.37x
Market
26.63x
PTPI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
2.26x
PTPI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTPI's financial health
Profit margin
Revenue
$1.4M
Net Income
-$662.0k
Profit Margin
-192.4%
PTPI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PTPI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.2M
Liabilities
$16.0M
Debt to equity
1.98
PTPI's short-term assets ($13.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTPI's short-term assets ($13.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTPI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
$0.0
Financing
-$2.0M
PTPI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTPI vs Pharmaceutical Stocks
Petros Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.